Behzad Najafian1, Camilla Tøndel2,3, Einar Svarstad3, Marie-Claire Gubler4, João-Paulo Oliveira5,6, Michael Mauer7,8. 1. Department of Pathology, University of Washington, Seattle, Washington; Najafian@uw.edu. 2. Department of Pediatrics, Haukland University Hospital, Bergen, Norway. 3. Institute of Clinical Medicine, University of Bergen, Bergen, Norway. 4. Institut National de la Santé et de la Recherche Médicale (INSERM) U1163, Imagine Institute, Necker-Enfants Malades Hospital, Paris, France. 5. Service of Medical Genetics, São João University Hospital, Porto, Portugal. 6. Department of Medical Genetics, Faculty of Medicine, i3S (Institute for Research and Innovation in Health), University of Porto, Porto, Portugal. 7. Department of Pediatrics, University of Minnesota, Minneapolis, Minnesota; and. 8. Department of Medicine, University of Minnesota, Minneapolis, Minnesota.
Abstract
BACKGROUND: In males with classic Fabry disease, the processes leading to the frequent outcome of ESKD are poorly understood. Defects in the gene encoding α-galactosidase A lead to accumulation of globotriaosylceramide (GL3) in various cell types. In the glomerular podocytes, accumulation of GL3 progresses with age. Of concern, podocytes are relatively resistant to enzyme replacement therapy and are poorly replicating, with little ability to compensate for cell loss. METHODS: In this study of 55 males (mean age 27 years) with classic Fabry disease genotype and/or phenotype, we performed unbiased quantitative morphometric electron microscopic studies of biopsied kidney samples from patients and seven living transplant donors (to serve as controls). We extracted clinical information from medical records and clinical trial databases. RESULTS: Podocyte GL3 volume fraction (proportion of podocyte cytoplasm occupied by GL3) increased with age up to about age 27, suggesting that increasing podocyte GL3 volume fraction beyond a threshold may compromise survival of these cells. GL3 accumulation was associated with podocyte injury and loss, as evidenced by increased foot process width (a generally accepted structural marker of podocyte stress and injury) and with decreased podocyte number density per glomerular volume. Worsening podocyte structural parameters (increasing podocyte GL3 volume fraction and foot process width) was also associated with increasing urinary protein excretion-a strong prognosticator of adverse renal outcomes in Fabry disease-as well as with decreasing GFR. CONCLUSIONS: Given the known association between podocyte loss and irreversible FSGS and global glomerulosclerosis, this study points to an important role for podocyte injury and loss in the progression of Fabry nephropathy and indicates a need for therapeutic intervention before critical podocyte loss occurs.
BACKGROUND: In males with classic Fabry disease, the processes leading to the frequent outcome of ESKD are poorly understood. Defects in the gene encoding α-galactosidase A lead to accumulation of globotriaosylceramide (GL3) in various cell types. In the glomerular podocytes, accumulation of GL3 progresses with age. Of concern, podocytes are relatively resistant to enzyme replacement therapy and are poorly replicating, with little ability to compensate for cell loss. METHODS: In this study of 55 males (mean age 27 years) with classic Fabry disease genotype and/or phenotype, we performed unbiased quantitative morphometric electron microscopic studies of biopsied kidney samples from patients and seven living transplant donors (to serve as controls). We extracted clinical information from medical records and clinical trial databases. RESULTS: Podocyte GL3 volume fraction (proportion of podocyte cytoplasm occupied by GL3) increased with age up to about age 27, suggesting that increasing podocyte GL3 volume fraction beyond a threshold may compromise survival of these cells. GL3 accumulation was associated with podocyte injury and loss, as evidenced by increased foot process width (a generally accepted structural marker of podocyte stress and injury) and with decreased podocyte number density per glomerular volume. Worsening podocyte structural parameters (increasing podocyte GL3 volume fraction and foot process width) was also associated with increasing urinary protein excretion-a strong prognosticator of adverse renal outcomes in Fabry disease-as well as with decreasing GFR. CONCLUSIONS: Given the known association between podocyte loss and irreversible FSGS and global glomerulosclerosis, this study points to an important role for podocyte injury and loss in the progression of Fabry nephropathy and indicates a need for therapeutic intervention before critical podocyte loss occurs.
Authors: Jeffrey B Hodgin; Markus Bitzer; Larysa Wickman; Farsad Afshinnia; Su Q Wang; Christopher O'Connor; Yan Yang; Chrysta Meadowbrooke; Mahboob Chowdhury; Masao Kikuchi; Jocelyn E Wiggins; Roger C Wiggins Journal: J Am Soc Nephrol Date: 2015-06-02 Impact factor: 10.121
Authors: Helen C Looker; Michael Mauer; Pierre-Jean Saulnier; Jennifer L Harder; Viji Nair; Carine M Boustany-Kari; Paolo Guarnieri; Jon Hill; Cordell A Esplin; Matthias Kretzler; Robert G Nelson; Behzad Najafian Journal: J Am Soc Nephrol Date: 2019-06 Impact factor: 10.121
Authors: Jocelyn E Wiggins; Meera Goyal; Silja K Sanden; Bryan L Wharram; Kerby A Shedden; David E Misek; Rork D Kuick; Roger C Wiggins Journal: J Am Soc Nephrol Date: 2005-08-24 Impact factor: 10.121
Authors: Alberto Ortiz; Ademola Abiose; Daniel G Bichet; Gustavo Cabrera; Joel Charrow; Dominique P Germain; Robert J Hopkin; Ana Jovanovic; Aleš Linhart; Sonia S Maruti; Michael Mauer; João P Oliveira; Manesh R Patel; Juan Politei; Stephen Waldek; Christoph Wanner; Han-Wook Yoo; David G Warnock Journal: J Med Genet Date: 2016-03-18 Impact factor: 6.318
Authors: Cassiano Augusto Braga Silva; Luis Gustavo Modelli de Andrade; Maria Helena Vaisbich; Fellype de Carvalho Barreto Journal: J Bras Nefrol Date: 2022 Apr-Jun
Authors: Cassiano Augusto Braga Silva; José A Moura-Neto; Marlene Antônia Dos Reis; Osvaldo Merege Vieira Neto; Fellype Carvalho Barreto Journal: Can J Kidney Health Dis Date: 2021-01-19